CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (109)
2024
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
2023
-
Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis
Alimentary Pharmacology and Therapeutics, Vol. 57, Núm. 6, pp. 610-619
2022
-
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 4, pp. 614-624
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
-
Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis—Author’s reply
Alimentary Pharmacology and Therapeutics
-
Editorial: real-world safety of tofacitinib in ulcerative colitis
Alimentary Pharmacology and Therapeutics
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
Journal of Clinical Medicine, Vol. 11, Núm. 13
-
Real-World Effectiveness and Safety of Tofacitinib in Patients with Ulcerative Colitis: Systematic Review with Meta-Analysis
Inflammatory Bowel Diseases, Vol. 28, Núm. 1, pp. 32-40
-
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641
-
Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings
Rheumatology International
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: An example of evidence-based extrapolation
Revista Espanola de Enfermedades Digestivas
-
Can COVID-19 Trigger De Novo Inflammatory Bowel Disease?
Gastroenterology
-
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Journal of Crohn's and Colitis, Vol. 15, Núm. 6, pp. 879-913
-
Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures
Inflammatory bowel diseases, Vol. 27, Núm. 6, pp. 864-869